These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 1765161)

  • 1. Nature of papain products resulting from inactivation by a peptidyl O-acyl hydroxamate.
    Ménard R; Feng R; Storer AC; Robinson VJ; Smith RA; Krantz A
    FEBS Lett; 1991 Dec; 295(1-3):27-30. PubMed ID: 1765161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-peptidyl-O-carbamoyl amino acid hydroxamates: irreversible inhibitors for the study of the S2' specificity of cysteine proteinases.
    Brömme D; Kirschke H
    FEBS Lett; 1993 May; 322(3):211-4. PubMed ID: 8486151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-peptidyl, O-acyl hydroxamates: comparison of the selective inhibition of serine and cysteine proteinases.
    Demuth HU; Schierhorn A; Bryan P; Höfke R; Kirschke H; Brömme D
    Biochim Biophys Acta; 1996 Jul; 1295(2):179-86. PubMed ID: 8695644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of cysteine proteases by peptidyl epoxides: characterization of the alkylation sites on the enzyme and the inactivator.
    Albeck A; Kliper S
    Biochem J; 2000 Feb; 346 Pt 1(Pt 1):71-6. PubMed ID: 10657241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of inhibition of cathepsin K by potent, selective 1, 5-diacylcarbohydrazides: a new class of mechanism-based inhibitors of thiol proteases.
    Bossard MJ; Tomaszek TA; Levy MA; Ijames CF; Huddleston MJ; Briand J; Thompson S; Halpert S; Veber DF; Carr SA; Meek TD; Tew DG
    Biochemistry; 1999 Nov; 38(48):15893-902. PubMed ID: 10625455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cysteine proteases such as papain are not inhibited by substrate analogue peptidyl boronic acids.
    Martichonok V; Jones JB
    Bioorg Med Chem; 1997 Apr; 5(4):679-84. PubMed ID: 9158866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel N-peptidyl-O-acyl hydroxamates: selective inhibitors of cysteine proteinases.
    Brömme D; Neumann U; Kirschke H; Demuth HU
    Biochim Biophys Acta; 1993 Oct; 1202(2):271-6. PubMed ID: 8399390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptidyl O-acyl hydroxamates: potent new inactivators of cathepsin B.
    Smith RA; Coles PJ; Spencer RW; Copp LJ; Jones CS; Krantz A
    Biochem Biophys Res Commun; 1988 Sep; 155(3):1201-6. PubMed ID: 3178802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ligand homologation and ligand reactivity on the apparent kinetic specificity of papain.
    Liu S; Hanzlik RP
    Biochim Biophys Acta; 1995 Jul; 1250(1):43-8. PubMed ID: 7612652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling the inhibition of peptide deformylase by hydroxamic acids: influence of the sulfur donor.
    Galardon E; Giorgi M; Artaud I
    Dalton Trans; 2007 Mar; (10):1047-52. PubMed ID: 17325780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptidyl beta-homo-aspartals (3-amino-4-carboxybutyraldehydes): new specific inhibitors of caspases.
    Bajusz S; Fauszt I; Németh K; Barabás E; Juhász A; Patthy M; Bauer PI
    Biopolymers; 1999; 51(1):109-18. PubMed ID: 10380358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1-Peptidyl-2-haloacetyl hydrazines as active site directed inhibitors of papain and cathepsin B.
    Giordano C; Calabretta R; Gallina C; Consalvi V; Scandurra R
    Farmaco; 1991 Dec; 46(12):1497-516. PubMed ID: 1821630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide aldehydes and nitriles as transition state analog inhibitors of cysteine proteases.
    Dufour E; Storer AC; Ménard R
    Biochemistry; 1995 Jul; 34(28):9136-43. PubMed ID: 7619812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationships of second-generation hydroxamate botulinum neurotoxin A protease inhibitors.
    Capková K; Yoneda Y; Dickerson TJ; Janda KD
    Bioorg Med Chem Lett; 2007 Dec; 17(23):6463-6. PubMed ID: 17951059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structure of a papain-E-64 complex.
    Varughese KI; Ahmed FR; Carey PR; Hasnain S; Huber CP; Storer AC
    Biochemistry; 1989 Feb; 28(3):1330-2. PubMed ID: 2713367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of proteases with enkephalin-analogue inhibitors.
    Demuth HU; Silberring J; Nyberg F
    J Enzyme Inhib; 1991; 4(4):289-98. PubMed ID: 1669830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of substance P degradation in rat brain preparations by peptide hydroxamic acids.
    Laufer R; Ewenson A; Gilon C; Chorev M; Selinger Z
    Eur J Biochem; 1985 Jul; 150(1):135-40. PubMed ID: 2410267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptidyl cyclopropenones: reversible inhibitors, irreversible inhibitors, or substrates of cysteine proteases?
    Cohen M; Bretler U; Albeck A
    Protein Sci; 2013 Jun; 22(6):788-99. PubMed ID: 23553793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of protease inhibitors on the basis of substrate stereospecificity.
    Kim DH
    Biopolymers; 1999; 51(1):3-8. PubMed ID: 10380348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A re-appraisal of the structural basis of stereochemical recognition in papain. Insensitivity of binding-site-catalytic-site signalling to P2-chirality in a time-dependent inhibition.
    Templeton W; Kowlessur D; Thomas EW; Topham CM; Brocklehurst K
    Biochem J; 1990 Mar; 266(3):645-51. PubMed ID: 2327953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.